News
SPRO
1.470
-2.00%
-0.030
Weekly Report: what happened at SPRO last week (0408-0412)?
Weekly Report · 4d ago
Weekly Report: what happened at SPRO last week (0401-0405)?
Weekly Report · 04/08 09:19
Cantor Fitzgerald Reiterates Overweight on Spero Therapeutics
Benzinga · 04/04 13:45
Weekly Report: what happened at SPRO last week (0325-0329)?
Weekly Report · 04/01 09:18
Weekly Report: what happened at SPRO last week (0318-0322)?
Weekly Report · 03/25 09:19
Spero Therapeutics’ Robust Drug Pipeline and Positive Trial Advancements Prompt Buy Rating
TipRanks · 03/18 10:26
Weekly Report: what happened at SPRO last week (0311-0315)?
Weekly Report · 03/18 09:18
Spero Therapeutics files $300M mixed securities shelf
Healthcare Spero Therapeutics files $300M mixed securities shelf Mar. 15, 2024 4:45 p.m. The company filed a prospectus related to a mixed shelf offering to raise up to $300m. The stock is down 1.7% in the last week.
Seeking Alpha · 03/15 20:45
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Limbach Holdings, Inc. Fell 14.7% to $42.42 on Thursday. The company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates. Aptorum Group Limited and Presto Automation were among the stocks moving in today's mid-day session. Build-A-Bear Workshop and DICK'S Sporting Goods were also among the gainers.
Benzinga · 03/14 17:38
Why Robinhood Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Robinhood Markets, Inc. Shares rose sharply in today's pre-market trading after the company reported February trading metrics. The company's total funded customers grew to 23.6 million at the end of February. ShiftPixy, Inc., and Presto Automation Inc. Were among the stocks moving in pre- market trading.
Benzinga · 03/14 12:05
Spero Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Spero Therapeutics Inc reports quarterly adjusted earnings of 96 cents per share for the quarter ended in December. Revenue rose 55% to $73.52 million from the same quarter last year. The company reported quarterly income of $51.19 million. The mean earnings estimate of three analysts was for a loss of 10 cents.
Reuters · 03/14 03:43
TD Cowen Sticks to Its Hold Rating for Spero Therapeutics (SPRO)
TipRanks · 03/14 03:25
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates
NASDAQ · 03/13 21:10
Recap: Spero Therapeutics Q4 Earnings
Spero Therapeutics reported its Q4 earnings of $0.96. The company's revenue was up $26.08 million from the same period last year. SperoTherapeutics is expected to announce its earnings on Wednesday, March 13, 2024 at 4:05 p.m.
Benzinga · 03/13 20:15
*Spero Therapeutics Reiterates Expected Cash Runway Into Late 2025 >SPRO
Dow Jones · 03/13 20:03
*Spero Therapeutics 4Q EPS 96c >SPRO
Dow Jones · 03/13 20:03
Press Release: Spero Therapeutics Announces -2-
Spero will host a conference call and live webcast today at 4:30 p.m. ET. The conference call will be webcast live and can be accessed through Spero's website. The company is focused on developing novel treatments for rare diseases and bacterial infections. This press release may contain forward-looking statements. Tebipenem HBr studies have been funded in part with federal funds.
Dow Jones · 03/13 20:01
*Spero Therapeutics 4Q Net $51.2M >SPRO
Dow Jones · 03/13 20:01
Press Release: Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
Spero Therapeutics announces financial results for the fourth quarter and full year ended December 31, 2023. The company says it is on track for topline data from SPR720's Phase 2a proof-of-concept trial. Spero is developing an oral treatment for the treatment of mycobacterial pulmonary disease.
Dow Jones · 03/13 20:01
*Spero Therapeutics 4Q Rev $73.5M >SPRO
Dow Jones · 03/13 20:01
More
Webull provides a variety of real-time SPRO stock news. You can receive the latest news about Spero Therapeuti through multiple platforms. This information may help you make smarter investment decisions.
About SPRO
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with unmet need. Its lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Its partnership-directed programs consist of tebipenem HBr and SPR206. The tebipenem HBr is designed to be the oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. SPR206 is a direct acting intravenous (IV)-administered product candidate being developed as an option to treat MDR Gram-negative bacterial infections in the hospital setting.